Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA guidances

This article was originally published in The Gray Sheet

Executive Summary

Comments are due by July 18 on guidance documents for 510(k) submissions for permanent pacemaker leads, vascular prostheses, annuloplasty rings, extracorporeal blood circuit defoamers, cardiopulmonary bypass arterial line blood filters and oxygenators. The six devices were among 38 preamendments devices slated for reclassification from Class III to Class II in a March 15, 1999 proposed rule. Reclassification of the six devices has been put on hold, however, until the guidance documents are finalized (1"The Gray Sheet" June 28, 1999, p. 21)

You may also be interested in...

Downclassification Of Six Cardiovascular Devices To Class II Delayed

FDA is postponing the downclassification from Class III to Class II of six cardiovascular devices pending receipt of public comments on guidance documents intended to serve as special controls for the devices.

EWG Study Suggests More Than One In 10 Talc-Based Cosmetics Contain Asbestos

The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.

Atlas Biomed Unlocking Japan’s OTC Market With Direct-To-Consumer DNA And Microbiome Tests

Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus. 




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts